CN110520130A - 用于治疗癌症的usl-311 - Google Patents

用于治疗癌症的usl-311 Download PDF

Info

Publication number
CN110520130A
CN110520130A CN201880024349.5A CN201880024349A CN110520130A CN 110520130 A CN110520130 A CN 110520130A CN 201880024349 A CN201880024349 A CN 201880024349A CN 110520130 A CN110520130 A CN 110520130A
Authority
CN
China
Prior art keywords
cancer
sdf
level
pyridine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880024349.5A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·理查森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proxmargan Co Ltd
Original Assignee
Proxmargan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proxmargan Co Ltd filed Critical Proxmargan Co Ltd
Publication of CN110520130A publication Critical patent/CN110520130A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880024349.5A 2017-03-10 2018-03-09 用于治疗癌症的usl-311 Pending CN110520130A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1703907.4A GB201703907D0 (en) 2017-03-10 2017-03-10 Novel therapies for cancer
GB1703907.4 2017-03-10
PCT/GB2018/050608 WO2018162924A1 (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN110520130A true CN110520130A (zh) 2019-11-29

Family

ID=58605592

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880024349.5A Pending CN110520130A (zh) 2017-03-10 2018-03-09 用于治疗癌症的usl-311

Country Status (14)

Country Link
US (1) US20200281937A1 (enExample)
EP (1) EP3592356A1 (enExample)
JP (1) JP2020514345A (enExample)
KR (1) KR20190128660A (enExample)
CN (1) CN110520130A (enExample)
AU (1) AU2018231664A1 (enExample)
BR (1) BR112019018482A2 (enExample)
CA (1) CA3055470A1 (enExample)
EA (1) EA201992130A1 (enExample)
GB (1) GB201703907D0 (enExample)
IL (1) IL269121A (enExample)
MX (1) MX2019010679A (enExample)
SG (1) SG11201908166UA (enExample)
WO (1) WO2018162924A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
PL3277284T3 (pl) 2015-04-02 2021-03-08 Proximagen, Llc Nowe terapie nowotworu

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103282360A (zh) * 2010-10-14 2013-09-04 普罗克斯马根有限公司 Cxcr4受体拮抗剂
WO2016157149A1 (en) * 2015-04-02 2016-10-06 Proximagen Limited Novel therapies for cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103282360A (zh) * 2010-10-14 2013-09-04 普罗克斯马根有限公司 Cxcr4受体拮抗剂
WO2016157149A1 (en) * 2015-04-02 2016-10-06 Proximagen Limited Novel therapies for cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAISUKE IZUMI等: "CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin b1 clustering and invasiveness in gastric cancer", 《INTERNATIONAL JOURNAL OF CANCER》 *
MARGITTA M.RETZ等: "CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells", 《INT J CANCER》 *

Also Published As

Publication number Publication date
SG11201908166UA (en) 2019-10-30
AU2018231664A1 (en) 2019-09-26
EA201992130A1 (ru) 2020-02-04
CA3055470A1 (en) 2018-09-13
BR112019018482A2 (pt) 2020-04-14
EP3592356A1 (en) 2020-01-15
US20200281937A1 (en) 2020-09-10
GB201703907D0 (en) 2017-04-26
KR20190128660A (ko) 2019-11-18
JP2020514345A (ja) 2020-05-21
MX2019010679A (es) 2020-02-05
IL269121A (en) 2019-11-28
WO2018162924A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
US11369616B2 (en) Drug combination and its use in therapy
CN111971279B (zh) 趋化因子受体调节剂及其用途
TWI603733B (zh) Ｒｅｔ抑制劑
EP3122742B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
CN108464981B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
RU2747645C2 (ru) Новые соединения
CN110520130A (zh) 用于治疗癌症的usl-311
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
JP2024520461A (ja) Ｅｇｆｒ及び／又はｈｅｒ２に異常を有するがんを有する対象の治療方法
CN113302188A (zh) 作为tam及met激酶抑制剂的喹啉化合物
EP4599885A2 (en) Compounds for the treatment of glioblastoma
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
TW202515577A (zh) 患有具有ｅｇｆｒ畸變的非小細胞肺癌之個體的治療方法
AU2024307787A1 (en) Treatment methods for subjects with non-small cell lung cancer having an aberration in egfr
HK1257617A1 (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
HK40053753A (en) Quinoline compounds as inhibitors of tam and met kinases
HK1257617B (en) Use of a composition for inhibiting tie2 kinase in the manufacture of a medicament for treating cancer
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191129

WD01 Invention patent application deemed withdrawn after publication